Silence Therapeutics (SLN) Receivables - Net (2019 - 2025)

Silence Therapeutics (SLN) has 7 years of Receivables - Net data on file, last reported at $28000.0 in Q3 2025.

• For the quarter ending Q3 2025, Receivables - Net changed N/A year-over-year to $28000.0; the trailing twelve-month figure through Sep 2025 stood at $28000.0 (changed N/A YoY), and the FY2024 full-year result was $972000.0, up 235.17% from the prior year.
• Receivables - Net declined to $28000.0 in Q3 2025, from $85000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $1.1 million in Q4 2022 to a low of $28000.0 in Q3 2025.
• A 5-year average of $418343.4 and a median of $282982.6 in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net slumped 98.85% in 2021 and jumped 243.48% in 2024, its largest moves.
• Tracing SLN's Receivables - Net over 5 years: stood at $446191.5 in 2021, then jumped by 140.53% to $1.1 million in 2022, then plunged by 73.63% to $282982.6 in 2023, then jumped by 243.48% to $972000.0 in 2024, then plunged by 97.12% to $28000.0 in 2025.
• Business Quant data shows SLN's Receivables - Net at $28000.0 in Q3 2025, $85000.0 in Q2 2025, and $41000.0 in Q1 2025.